About: http://data.cimple.eu/news-article/7c2469f56204c170adf664873df6ef1fa6d5cfe6c61f369d2130b270

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/7c2469f56204c170adf664873df6ef1fa6d5cfe6c61f369d2130b270 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The US biotech firm Moderna said Tuesday it would enter the final stage of its human trials for its COVID-19 vaccine on July 27, after promising early results were published in a journal. The Phase 3 trial will recruit 30,000 participants in the US, with half to receive the vaccine at 100 microgram dose levels, and the other half will receive a placebo. It is designed to learn whether the vaccine can prevent infection by the SARS-CoV-2 virus, or, if people still get infected, whether it can prevent the infection progressing toward symptoms. If they do get symptoms, the vaccine can still be considered a success if it stops severe cases of COVID-19. The study should run until October 27, according to its page on clinicaltrials.gov. The announcement came after the New England Journal of Medicine on Tuesday published results from the first stage of Moderna's vaccine trial, which showed the first 45 participants all developed antibodies to the virus. Moderna is in pole position in the global race to find a vaccine against the coronavirus, which has infected more than 13.2 million people and killed 570,000. China's SinoVac is also at an advanced stage, Phase 2, while the Russian news agency TASS has announced Russian researchers have completed clinical trials on a vaccine, though they have not shared data. Scientists caution that the first vaccines to come to market may not be the most effective or safest. The Moderna vaccine belongs to a new class of vaccine that uses genetic material, in the form of RNA, to encode the information needed to grow the virus' spike protein inside the human body, in order to trigger an immune response. The spike protein is a part of the virus it uses to invade human cells, but by itself is relatively harmless. The advantage of this technology is that it bypasses the need to manufacture viral proteins in the lab, shaving months off the standardization process and helping to ramp up mass production. But no vaccines based on this platform have previously received regulatory approval. ia/bgs
schema:headline	Moderna COVID-19 vaccine enters final stage trial July 27: statement
schema:mentions	RNA virus TASS Shaving Immune response New England Protein Antibody Ia (cuneiform) Russian language Virus Vaccine China Coronavirus Severe acute respiratory syndrome coronavirus 2 Microgram The Advantage ClinicalTrials.gov Pole position
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-07-14 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	80 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software